A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Recruiting now · Phase 2

Conditions studied: IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy

In brief

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)

Key facts

Study ID

NCT06419205

Run by

Akebia Therapeutics

People needed

30

Starts

2026-07-30

Expected to finish

2028-02-01

Last updated by the study team

2026-08-04

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigator Site #1 — Lawrenceville, Georgia, United States (enrolling)
• Investigator Site #2 — São Paulo, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.